Christian Silva-Rengifo

Christian Silva-Rengifo

Auto-generated profile, based on publicly available information

Christian Silva-Rengifo

Doyenne Institute, High Quality Diagnosis for Deep Endometriosis and Advanced Pelvic Surgery, Mexico City, Mexico

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Travel Medicine and Infectious Disease
Verified
Journal Article
Closed access
JBJoshuan J. Barboza
Joshuan J. Barboza
DCDiego Chambergo-Michilot
Diego Chambergo-Michilot
MVMariana Velasquez-Sotomayor
Mariana Velasquez-Sotomayor
CSChristian Silva-Rengifo
Christian Silva-Rengifo
CDCarlos Diaz-Arocutipa
Carlos Diaz-Arocutipa
Alfonso J. Rodriguez-MoralesAlfonso J. Rodriguez-Morales
Alfonso J. Rodriguez-Morales

27 January 2021 in medRxiv
Verified
Preprint
Open access
PDF file
ACAlex Castañeda-Sabogal
Alex Castañeda-Sabogal
DCDiego Chambergo-Michilot
Diego Chambergo-Michilot
CTCarlos J. Toro-Huamanchumo
Carlos J. Toro-Huamanchumo
CSChristian Silva-Rengifo
Christian Silva-Rengifo
Jose A. Gonzales ZamoraJose A. Gonzales Zamora
Jose A. Gonzales Zamora
JBJoshuan J. Barboza
Joshuan J. Barboza
Background: To assess the outcomes of ivermectin in ambulatory and hospitalized patients with COVID-19. Methods: Five databases and websites for preprints were searched until January 2021 for randomized controlled trials (RCTs) and retrospective cohorts assessing ivermectin versus control in ambulatory and hospitalized participants. The primary outcome was overall mortality. Secondary outcome was recovered patients. For meta-analysis, random-effects and inverse variance meta-analyses with logarithmic transformation were performed. ROBINS-I for cohort studies, and the Cochrane Risk of Bias 2.0 tool for trials were used. The strength of evidence was assessed using GRADE. Results: After the selection, twelve studies (five retrospective cohort studies, six randomized clinical trials and one case series), were included. In total, 7412 participants were reported, the mean age was 47.5 (SD 9.5) years, and 4283 (58%) were male. Ivermectin was not associated with reduced mortality (logRR: 0.89, 95% CI 0.09 to 1.70, p = 0.04, I 2 = 84.7%), or reduced patient recovery (logRR 5.52, 95% CI -24.36 to 35.4, p = 0.51, I 2 = 92.6%). All studies had a high risk of bias, and showed a very low certainty of the evidence. Conclusions: There insufficient certainty and quality of evidence to recommend the use of ivermectin to prevent or treat ambulatory or hospitalized patients with COVID-19.

27 April 2023 in Cureus
Verified
Journal Article
Open access
PDF file
CSChristian Silva-Rengifo
Christian Silva-Rengifo
AAAngelica Asencio
Angelica Asencio
OSOscar Salirrosas
Oscar Salirrosas
CSChristian Silva Rengifo Sr.
Christian Silva Rengifo Sr.
Xanthogranulomatous endometritis (XGE) or histiocytic endometritis is a chronic inflammatory pathology of rare presentation, characterized by an exaggerated inflammatory infiltrate that can mimic an endometrial carcinoma. We report two cases of this disease, one of them with a classic presentation of endometritis and the other one with a severe compromise in which the clinical presentation and imaging findings suggested a possible endometrial carcinoma. Knowledge of this unusual and rare pathology, including its etiopathogenesis, is important since it can be included in the differential diagnosis of endometrial carcinoma and, therefore, whenever it is found, to avoid excessive treatment.

2 March 2026
Verified
Book Chapter
Open access
PDF file
PHPerla Sofía Vera Hernández
Perla Sofía Vera Hernández
Ramiro Cabrera CarrancoRamiro Cabrera Carranco
Ramiro Cabrera Carranco
ABAna Gabriela Sierra Brozon
Ana Gabriela Sierra Brozon
WKWilliam Kondo
William Kondo
JOJordanna Santanna Diniz e Moura Osaki
Jordanna Santanna Diniz e Moura Osaki
CRChristian Silva Rengifo
Christian Silva Rengifo
Endometriosis is a chronic, estrogen-dependent inflammatory disease influenced by complex neuroimmune interactions and pain chronification mechanisms. Modern medical management is increasingly guided by a deeper understanding of neuroinflammation, peripheral and central sensitization, and immune dysregulation, moving beyond traditional hormonal suppression. This chapter will synthesize the latest evidence on precision medicine approaches, integrating pain phenotyping, molecular and inflammatory biomarkers, and mechanisms of treatment resistance. It will explore targeted pharmacologic strategies, including neuromodulators, selective progesterone receptor modulators, immunomodulatory and anti-fibrotic agents, as well as innovative non-hormonal therapies under investigation. Additionally, it will highlight research gaps and opportunities for translational applications. The aim is to provide a rigorous, mechanism-based framework for individualized, effective, and biologically informed medical treatment of endometriosis.

18 August 2020 in ACTA MEDICA PERUANA
Verified
Journal Article
Open access
PDF file
CSChristian Silva-Rengifo
Christian Silva-Rengifo
MVMariana Velásquez-Sotomayor
Mariana Velásquez-Sotomayor
JBJoshuan J. Barboza
Joshuan J. Barboza
Fin del confinamiento y enfermedad similar

30 June 2021 in Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo
Verified
Journal Article
Open access
CSChristian Silva-Rengifo
Christian Silva-Rengifo
OSOrlanmdfo R. Salazar-Cruzado
Orlanmdfo R. Salazar-Cruzado
MVMariana Velásquez-Sotomayor
Mariana Velásquez-Sotomayor
JBJoshuan J. Barboza
Joshuan J. Barboza
Objetivo: El presente estudio se centró en determinar si la diferencia de hemoglobina del tercer y el primer trimestre de gestación mayor de – 1 (Delta de hemoglobina disminuido) es un factor de riesgo para el bajo peso al nacer en recién nacidos a término en el Hospital Belén de Trujillo. Material y métodos: Estudio de cohorte histórica. Se realizó un estudio de cohorte retrospectiva donde se incluyeron 218 neonatos, de acuerdo con los criterios de selección, los cuales fueron divididos en dos grupos: pacientes con delta de hemoglobina materna disminuida y no disminuida: aplicando el riesgo relativo y el test estadístico de chi-cuadrado. Resultados: La frecuencia de neonatos con bajo peso al nacer en mujeres embarazadas con delta de hemoglobina disminuida fue de 32/109 = 29 %; la frecuencia de bajo peso al nacer en las mujeres embarazadas con delta de hemoglobina no disminuida fue de 18/109 = 17 %. La delta de hemoglobina materna disminuida es un factor de riesgo para el bajo peso al nacer con un riesgo relativo de 1.78 [IC: 95 % (1.45 – 3.56) p < 0.05]. Conclusiones: La delta de hemoglobina materna disminuida es un factor de riesgo para el bajo peso al nacer en recién nacidos a término en el Hospital Belén de Trujillo.